Satellos Bioscience Inc.
MSCL.TO
TSX
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 31.81% | 163.77% | |||
| Gross Profit | -31.81% | -163.77% | |||
| SG&A Expenses | -7.43% | 24.68% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 21.13% | 31.33% | |||
| Operating Income | -21.13% | -31.33% | |||
| Income Before Tax | -19.92% | -34.37% | |||
| Income Tax Expenses | 33.33% | -43.10% | |||
| Earnings from Continuing Operations | -19.96% | -33.75% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -19.96% | -33.75% | |||
| EBIT | -21.13% | -31.33% | |||
| EBITDA | -21.13% | -31.32% | |||
| EPS Basic | -6.15% | -12.22% | |||
| Normalized Basic EPS | -6.15% | -12.70% | |||
| EPS Diluted | -6.15% | -12.22% | |||
| Normalized Diluted EPS | -6.15% | -12.70% | |||
| Average Basic Shares Outstanding | 13.00% | 19.20% | |||
| Average Diluted Shares Outstanding | 13.00% | 19.20% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||